JP2010519181A5 - - Google Patents

Download PDF

Info

Publication number
JP2010519181A5
JP2010519181A5 JP2009548468A JP2009548468A JP2010519181A5 JP 2010519181 A5 JP2010519181 A5 JP 2010519181A5 JP 2009548468 A JP2009548468 A JP 2009548468A JP 2009548468 A JP2009548468 A JP 2009548468A JP 2010519181 A5 JP2010519181 A5 JP 2010519181A5
Authority
JP
Japan
Prior art keywords
substituted
amino
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519181A (ja
JP5461197B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/052778 external-priority patent/WO2008097835A2/en
Publication of JP2010519181A publication Critical patent/JP2010519181A/ja
Publication of JP2010519181A5 publication Critical patent/JP2010519181A5/ja
Application granted granted Critical
Publication of JP5461197B2 publication Critical patent/JP5461197B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009548468A 2007-02-02 2008-02-01 代謝障害を処置するための組成物および方法 Expired - Fee Related JP5461197B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88799407P 2007-02-02 2007-02-02
US60/887,994 2007-02-02
US1231007P 2007-12-07 2007-12-07
US61/012,310 2007-12-07
PCT/US2008/052778 WO2008097835A2 (en) 2007-02-02 2008-02-01 Compositions and methods for the treatment of metabolic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014005460A Division JP5878937B2 (ja) 2007-02-02 2014-01-15 代謝障害を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2010519181A JP2010519181A (ja) 2010-06-03
JP2010519181A5 true JP2010519181A5 (enExample) 2012-03-08
JP5461197B2 JP5461197B2 (ja) 2014-04-02

Family

ID=39682342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009548468A Expired - Fee Related JP5461197B2 (ja) 2007-02-02 2008-02-01 代謝障害を処置するための組成物および方法
JP2014005460A Expired - Fee Related JP5878937B2 (ja) 2007-02-02 2014-01-15 代謝障害を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014005460A Expired - Fee Related JP5878937B2 (ja) 2007-02-02 2014-01-15 代謝障害を処置するための組成物および方法

Country Status (7)

Country Link
US (3) US8207196B2 (enExample)
EP (1) EP2120580B1 (enExample)
JP (2) JP5461197B2 (enExample)
CN (1) CN101674730B (enExample)
AU (1) AU2008214095B2 (enExample)
CA (1) CA2677264C (enExample)
WO (1) WO2008097835A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101674730B (zh) * 2007-02-02 2014-09-10 贝勒医学院 用于治疗代谢疾病的组合物和方法
US9187485B2 (en) * 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9233941B2 (en) * 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9212179B2 (en) * 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2012516329A (ja) 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
MX2013003101A (es) 2010-09-17 2013-09-26 Purdue Pharma Lp Compuestos de piridina y sus usos.
WO2012048303A2 (en) * 2010-10-07 2012-04-12 Columbia University METHOD FOR TREATING CANCER HARBORING A p53 MUTATION
CA2814688A1 (en) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013110007A1 (en) * 2012-01-18 2013-07-25 The Trustees Of Columbia University In The City Of New York USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
US9750758B2 (en) 2012-06-25 2017-09-05 Thomas Jefferson University Compositions and methods for treating cancer with aberrant lipogenic signaling
US20140275178A1 (en) * 2013-03-13 2014-09-18 Musc Foundation For Research Development Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
CN106029072A (zh) * 2013-08-28 2016-10-12 麦迪韦逊技术股份有限公司 杂环化合物和使用方法
CA2922703A1 (en) * 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
KR20160115999A (ko) 2014-02-14 2016-10-06 더 유니버시티 오브 브리티쉬 콜롬비아 치료제로서의 인간 안드로겐 수용체 dna-결합 도메인(dbd) 화합물 및 그의 사용 방법
US9873689B2 (en) 2014-11-07 2018-01-23 Fgh Biotech, Inc. Synthesis of fatostatin based polycyclic compounds
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
WO2016131192A1 (en) * 2015-02-17 2016-08-25 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Compounds and methods for inducing browning of white adipose tissue
CA2977539A1 (en) * 2015-03-04 2016-09-09 Medivation Technologies, Inc. Sterol regulatory element-binding proteins (srebps) inhibitors
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use
HK1245664B (en) * 2015-05-29 2020-06-26 Changiz Taghibiglou Polypeptides to treat skin conditions associated with overproduction of sebum
US10590063B2 (en) 2015-11-06 2020-03-17 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of fatty acid metabolism disorders
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
CA3022395C (en) 2016-04-29 2024-11-05 Fgh Biotech, Inc. PYRAZOLE COMPOUNDS SUBSTITUTES FOR THE TREATMENT OF DISEASES
EP3510027B1 (en) 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
KR101869308B1 (ko) * 2017-02-28 2018-06-20 대구가톨릭대학교산학협력단 Srebp-1 디코이 올리고디옥시뉴클레오티드 및 이를 유효성분으로 함유하는 지방간 질환의 예방 또는 치료용 약학 조성물
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
AU2019212959A1 (en) 2018-01-29 2020-09-17 Capulus Therapeutics, Llc SREBP inhibitors comprising a 6-membered central ring
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
CN113631163A (zh) * 2019-01-28 2021-11-09 卡普勒斯疗法有限责任公司 包括噻吩中心环的srebp抑制剂
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
WO2021035031A1 (en) * 2019-08-21 2021-02-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of phospholipid synthesis and methods of use
EP4096659A4 (en) * 2020-01-27 2023-10-18 Capulus Therapeutics, LLC SREBP INHIBITORS COMPRISING A THIOPHENIC RING
US12186297B2 (en) * 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
EP4531871A2 (en) * 2022-05-25 2025-04-09 Amgen Inc. Rnai constructs for inhibiting scap expression and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791200A (en) 1987-06-22 1988-12-13 Ortho Pharmaceutical Corporation 2-substituted-4-aryl-substituted thiazoles
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
EP1130017B1 (en) * 1990-11-30 2005-06-15 Otsuka Pharmaceutical Co., Ltd. Azole derivatives and their use as superoxide radical inhibitors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04282326A (ja) * 1991-03-08 1992-10-07 Yuki Gosei Kogyo Co Ltd 非対称な三環系化合物の製造法
EP0590060B1 (en) 1991-06-21 1997-09-17 University Of Cincinnati Orally administrable therapeutic proteins and method of making
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
JPH1179993A (ja) * 1997-09-05 1999-03-23 Sumitomo Pharmaceut Co Ltd 免疫抑制剤
JPH11186479A (ja) 1997-12-22 1999-07-09 Toyo Commun Equip Co Ltd 放熱板付き表面実装部品
BR9911752A (pt) * 1998-07-01 2001-04-03 Takeda Chemical Industries Ltd Agente de regulagem da função do receptor relacionado com a retinóide, derivados de oxazol, de imidazol e de tiazol, composto, processo para regular uma função de receptor relacionado com a retinóide, e, uso de um derivado
JP2000080086A (ja) * 1998-07-01 2000-03-21 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
US6537514B1 (en) 1999-10-26 2003-03-25 Praxair Technology, Inc. Method and apparatus for producing carbon dioxide
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE60139639D1 (de) 2000-12-08 2009-10-01 Takeda Pharmaceutical Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
IL157491A0 (en) * 2001-02-21 2004-03-28 Nps Pharmeceuticals Inc Heteropolycyclic compounds and pharmaceutical compositions containing the same
US7153889B2 (en) * 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
CA2523808A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
KR20070045226A (ko) 2004-08-03 2007-05-02 와이어쓰 심혈관 질환 치료에 유용한 인다졸
AR051597A1 (es) * 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
WO2006080406A1 (ja) 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
EP1893562A4 (en) * 2005-06-14 2010-04-28 Merck Frosst Canada Ltd REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE-A AND -B
JP2008546836A (ja) * 2005-06-28 2008-12-25 アストラゼネカ アクチボラグ 新規な用途
WO2007062222A2 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
CN101674730B (zh) * 2007-02-02 2014-09-10 贝勒医学院 用于治疗代谢疾病的组合物和方法
CN103842441B (zh) * 2011-10-04 2015-12-23 道康宁公司 含铁(iii)络合物和缩合反应催化剂、制备该催化剂的方法及含有该催化剂的组合物

Similar Documents

Publication Publication Date Title
JP2010519181A5 (enExample)
KR101179087B1 (ko) 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법
RU2461551C2 (ru) Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
RU2009118602A (ru) Производное индола
JP2009513563A5 (enExample)
AU2007265453A2 (en) Human protein tyrosine phosphatase inhibitors and methods of use
JP2010506825A5 (enExample)
JP2004534035A5 (enExample)
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
WO2007123269A1 (ja) アゾールカルボキサミド誘導体
JP2006516251A5 (enExample)
JP2016534124A5 (enExample)
KR20080034436A (ko) 암 치료에 사용되는 티아졸 유도체 및 유사체
RU2004129285A (ru) Производные тиазола в качестве антагонистов рецептора npy
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
CN101506180B (zh) 人蛋白酪氨酸磷酸酶抑制剂及使用方法
CN101237866A (zh) 噻唑类衍生物和类似物在游离脂肪酸引起的疾病中的应用
RU2435763C2 (ru) Ингибиторы тирозинфосфатазы белка человека и способы применения
JP2004513923A5 (enExample)
RU2005141516A (ru) Производные анилина
WO2006125285B1 (en) Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
HK1129387B (en) Human protein-tyrosine phosphatase inhibitors and methods of use
HRP20110716T1 (hr) Aril dikarboksamidi